The PART study is designed to evaluate the feasibility and potential benefit of continuing immunosuppressive therapy (IMSN) after kidney transplant failure, specifically to reduce the risk of allosensitization, which complicates the potential for future kidney transplantation. Transplantation remains the preferred treatment for kidney failure but often does not provide a permanent solution, with many transplanted kidneys failing within 12 years. This necessitates either dialysis or a second transplant.
A significant barrier to repeat kidney transplantation is the phenomenon of allosensitization. Allosensitization occurs when the immune system becomes sensitized to foreign human leukocyte antigen (HLA) markers from a failed kidney transplant. This immune response makes it difficult to match patients with subsequent donor kidneys, severely limiting their chances of receiving a second transplant. One of the current practices to mitigate allosensitization involves the continuation of immunosuppressive therapy after kidney transplant failure to reduce immune reactivity to the failed transplant. However, there is insufficient controlled, prospective evidence that this approach is effective in preventing further sensitization or improving outcomes.
Additionally, continuing IMSN after transplant failure carries significant risks, including increased susceptibility to infections, cardiovascular disease, and cancers, all of which contribute to patient morbidity. The current consensus in transplant guidelines recommends discontinuing IMSN after a year post-transplant, yet a multi-center prospective observational study has shown considerable practice variation in Canada, with 65% of patients continuing IMSN beyond the recommended time frame.
This pilot study, which is part of the larger planned PART trial, aims to determine the feasibility of continuing IMSN for two years after transplant failure, compared to withdrawing IMSN at six months. Specifically, the study seeks to demonstrate whether such an intervention can result in a clinically meaningful reduction in allosensitization while maintaining an acceptable level of safety. The findings from this pilot will provide critical data on the feasibility of recruitment, adherence to treatment protocols, and the collection of necessary event outcomes, which will inform the design of a larger, definitive trial.
Study Objectives and Design
The objectives of the PART pilot study are multifaceted. The primary goal is to assess the feasibility of continuing IMSN for two years post-transplant failure. This includes:
Adherence: The study aims to show that more than 80% of enrolled patients adhere to at least 80% of their prescribed IMSN according to the study protocol.
Enrollment: The study aims to demonstrate an enrollment rate of 0.66 patients per month (or 8 patients per 12-month period) across 12 pilot sites, resulting in a total of 96 patients enrolled.
Loss to Follow-up: The goal is to have a loss to follow-up rate of less than 5%, which aligns with rates seen in previous randomized controlled trials (RCTs) involving dialysis patients.
Secondary objectives include validating event outcome rates from prior observational studies to estimate sample size for a definitive trial. These outcomes will include:
Primary efficacy outcome: A clinically significant increase in sensitization, defined by a significant rise in the calculated panel reactive antibody (cPRA) level.
Repeat transplantation rates as a secondary measure of success. Safety outcomes: This includes monitoring for adverse events such as death, new cancer diagnoses, graft intolerance syndrome, hospitalization for infections, and adrenal insufficiency.
Residual renal function: As a potential surrogate marker for dialysis survival, the study will examine if IMSN can help preserve kidney function in patients whose transplant has failed.
The study will be a multi-center, randomized controlled trial with 12 participating centers, and will enroll a total of 96 patients. These patients will be randomized to either continue IMSN for two years or withdraw from IMSN by six months post-dialysis initiation.
Statistical Considerations and Power Analysis
The primary safety endpoints in the study will include critical events such as death, new cancer diagnoses, graft intolerance syndrome, hospitalization for infection, high levels of sensitization (cPRA ≥95%), and adrenal insufficiency. Secondary validating endpoints will include the rate of clinically relevant increases in sensitization, repeat transplantation rates, residual renal function, health-related quality of life, and patient perspectives on IMSN use post-transplant failure.
The statistical analysis will be conducted to ensure robust data collection and analysis for the definitive trial. Each of the 12 pilot sites will randomize 8 patients during the 12-month recruitment period. This provides an overall sample size of 96 patients. The sample size will be sufficient to generate a 95% confidence interval for adherence, assuming a true adherence rate of 80%. These data will be essential in refining the sample size estimates for the definitive PART trial, which will involve approximately 780 patients. The definitive trial will aim for more than 90% power to demonstrate a 30% reduction in sensitization for patients continuing IMSN for two years compared to those withdrawing from IMSN by 180 days after starting dialysis.
Key assumptions for the definitive trial include:
48% of patients stopping IMSN will experience a clinically significant increase in sensitization.
A hazard ratio (HR) of 0.7 for patients continuing IMSN is expected based on prior observational data showing a 40% lower incidence of sensitization in those who continue IMSN compared to those who stop.
Adherence: A target of 80% adherence is anticipated based on pilot trial outcomes.
Repeat transplant rate of 14%, as observed in the prospective observational study.
Death rate of 12% and a loss to follow-up rate of 7%, consistent with findings in previous observational studies.
The data from the PART pilot trial will thus help ensure that the future definitive trial is appropriately designed, with reliable sample size estimates and an accurate understanding of treatment adherence and safety outcomes.
